Based on next generation sequencing, Azenta Life Sciences’ high-throughput gene expression (HT-GEx) screening, similar to DRUG-Seq, is an optimal approach for drug discovery and analysis. Unlike microarrays which bear inherent limitations, this method offers rapid, unbiased 3' gene expression screening that provides a complete cell-to-data analysis of the transcriptome at a lower cost than standard RNA sequencing. Working directly from lysate, high-throughput gene expression screening saves both time and money by removing the need to purify RNA and performs 3’ transcript tagging that reduces the required sequencing depth.
|Metric||HT-GEx Screening||mRNA-Seq||Total RNA-Seq||Iso-Seq|
|Reads/Sample||~1-2M Reads||~10-30M Reads||~20-45M Reads||~1-2M Reads|
|Min. Sample Size||96/384||1||1||1|
|Starting Material||Cell Lysate||>20ng Total RNA||>100ng Total RNA||>1ug Total RNA|
|Selection Method||Poly(A) +||Poly(A) +||rRNA -||Poly(A) +|
|Detection Level||3' Tails of Genes||Poly(A) Transcript||All Transcript||Full-Length Poly(A) Transcript|
Suitable method | Preferred method | Not a suitable method
(In addition to standard deliverables)
Custom bioinformatics analysis and reports are available. Please contact us about how we can customize the analysis to answer your biological question.
Starting at just 2 weeks for quick target discovery
To rapidly scale up pilot or discovery projects
Exceeding manufacturers’ benchmarks
With this two-part webinar series, go beyond traditional transcriptomics and learn about the various NGS approaches available for gene expression analysis. In part 1, we take an in-depth look at various gene expression approaches, including RNA-Seq, single-cell RNA-Seq, digital spatial profiling, and more. In part 2, we explore the data generated from these approaches and how they can complement each other and confirm findings.
High-throughput technologies are critical in performing phenotypic profiling for drug discovery applications. In this tech note, Azenta Life Sciences discusses the challenges associated with traditional approaches, such as microarrays and RNA sequencing, and offers an optimized assay to achieve high-quality phenotypic profiling at a reduced cost for rapid drug discovery.
Azenta is a certified service provider for Illumina and other cutting-edge NGS platforms. For information on our NGS platforms, as well as recommended configurations of your projects, please visit the NGS Platforms page. Azenta does not guarantee data output or quality for sequencing-only projects.